Gilead Sciences’ White & Case counsel likened its client’s agreement with several pharmaceutical companies to not compete on HIV medication to the contracts lawyers sign when joining a firm in an attempt to dodge a class action lawsuit alleging the biotech company has violated antitrust and consumer-protection laws.
On Thursday, U.S. District Judge Edward Chen of the Northern District of California heard arguments to dismiss a consolidated class action complaint filed in August. The lawsuit, brought by 20 users of HIV therapies, claims Gilead joined forces with Bristol-Myers Squibb Co.; Japan Tobacco Inc.; and Johnson & Johnson subsidiary Janssen R&D Ireland to snuff competition on generic versions of HIV medications and extend the life of Gilead’s patents.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]